Monday, July 6, 2015 Last update: 8:33 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

The Best of U.S. Company Tech News - Updated Daily

Wednesday, May 16, 2012

  • Posted at 3:08 PM
    Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that data from two of its antibody-drug conjugate (ADC) programs, ADCETRIS (brentuximab vedotin) and ASG-5ME, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. A summary of ... read more
  • Posted at 3:05 PM
    Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the results of a retrospective subpopulation analysis of 183 patients with cancer from the company's two large Phase 3 trials, which showed the cancer patients with Clostridium difficile-associated diarrhea (CDAD) who were treated with DIFICID® (fidaxomicin) tablets experienced resolution of their diarrheal symptoms approximately two days faster than those treated with oral vancomycin. These results will be presented on June 2nd at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in ... read more
  • Posted at 3:04 PM
    CryoLife, Inc. (NYSE: CRY), a leading medical device company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of Hemosphere, Inc. Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction. CryoLife will begin the integration of the Hemosphere business immediately and expects to begin training its sales force on the HeRO Graft in ... read more
  • Posted at 3:02 PM
    Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE®) antibodies, designed to harness the body's cell-destroying T cells to kill cancer cells. Blinatumomab targets cells expressing CD19, ... read more
  • Posted at 3:01 PM
    Amgen (NASDAQ: AMGN) announced today results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall survival (OS) in patients whose tumors exhibited high MET protein expression. Full results of the study will be presented in an ... read more
  • Van Andel Research Institute And Dako Sign Agreement To License Cancer Diagnostic Tool --- GRAND RAPIDS, Mich. and GLOSTRUP, Denmark, May 16, 2012
    Posted at 3:00 PM
    Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 Antibody. The MET4 Antibody, developed by George F. Vande Woude, Ph.D. and Brian Cao, M.D. of VARI and Beatrice Knudsen, M.D., Ph.D., formerly of the Fred Hutchinson Cancer Research Center, has undergone and continues to undergo rigorous testing in numerous research labs worldwide. MET4 works exceptionally well with tumors expressing the human ... read more
  • Posted at 3:00 PM
    A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial (Photo: http://photos.prnewswire.com/prnh/20120516/MM07672 ) A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by ... read more
  • Posted at 3:00 PM
    McLane Advanced Technologies (MAT), a global provider of Information Technology and logistics solutions, is pleased to announce that Command Sergeant Major (Retired) Daniel K. Elder is now a Hall of Famer in the US Army Ordnance Corps. Mr. Elder, Senior Director of Business Development at MAT, has 26 years of vast military leadership, with 11 years' experience as a Command Sergeant Major. "We are extremely proud of Dan Elder," said McLane Advanced Technologies Vice President John Ballantyne. "His values and ... read more
  • Posted at 3:00 PM
    SRI Sarnoff's Iris on the Move® N-Glance(TM) identification system has received Lenel factory certification for its interface to Lenel's OnGuard® software system. SRI is now a member of the Lenel OpenAccess Alliance Program. This certification validates SRI's IOM N-Glance as a biometric product for Lenel access control systems. "SRI Sarnoff has completed the required factory testing at Lenel to validate the functionality of its interface to OnGuard," said Gidon Lissai, director of strategic alliances, Lenel. "We look forward to their ... read more
  • Posted at 3:00 PM
    Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012. LUX-Lung 3, which compares the investigational oral, once-daily therapy, afatinib, to pemetrexed/cisplatin, is the largest Phase III trial to date in first-line ... read more
  • Posted at 3:00 PM
    Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on its approved and investigational oncology compounds will be featured in ten oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. The data ... read more
  • Posted at 3:00 PM
    May 16, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5, 2012 in Chicago, Illinois. ... read more
  • Posted at 3:00 PM
    Emulex Corporation (NYSE:ELX), today announced it has been recognized as ‘perfect quality supplier of the year’ by Lenovo, an exclusive honor among Lenovo’s server and storage providers. The award was granted at Lenovo’s global supplier conference on May 9, 2012 in Chengdu, China and ... read more
  • Posted at 3:00 PM
    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated clinical data from the pivotal PACE trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in ... read more
  • Posted at 3:00 PM
    Agilent Technologies Inc. (NYSE:A) today announced that a quarterly dividend of 10 cents per share of common stock will be paid on July 25 to all shareholders of record as of the close of business on July 3. Agilent’s board of directors approved the initiation ... read more
  • Posted at 2:53 PM
    The second SpaceX demonstration launch for NASA's Commercial Orbital Transportation Services (COTS) is scheduled for liftoff on Saturday, May 19. The launch of the Falcon 9 rocket carrying a Dragon capsule will occur from Space Launch Complex 40 at Cape Canaveral Air Force Station in Florida. There is a single instantaneous launch opportunity at 4:55 a.m. EDT. (Logo: http://photos.prnewswire.com/prnh/20081007/38461LOGO) NASA Television launch commentary from Cape Canaveral begins at 3:30 a.m. During the flight, SpaceX's Dragon capsule will conduct a series of check-out ... read more
  • Posted at 2:41 PM
    In release dated May 03, 2012, end of second graph should read: SC’s diverse audience groups (sted: OOS’s diverse audience groups). The corrected release reads: AGENCYQ WINS THREE 2012 COMMUNICATOR AWARDS ... read more
  • Posted at 2:33 PM
    PRBA--The Rechargeable Battery Association has filed comments with the U.S. Pipeline and Hazardous Materials Safety Administration that "fully-support" proposed regulations that would harmonize U.S. requirements for the air shipment of lithium batteries with international rules adopted earlier this year. "Overall, PHMSA is moving in the right direction. The proposed regulations will advance the air safety goals that are most important to our members," said PRBA Executive Director George Kerchner. PRBA filed its comments along with others from a 20-member coalition of trade ... read more
  • Posted at 2:30 PM
    Sigma-Aldrich announced today that it has established a new $600 million revolving credit facility that will mature on May 10, 2017. The new facility replaces a $450 million revolving credit facility that was scheduled to mature on December 11, 2012. The $600 million facility will provide back-up liquidity for the commercial paper program and be used for general corporate purposes. Wells Fargo Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC served as co-lead ... read more
  • Posted at 2:25 PM
    T-Mobile is showing customers how two is better than one. For a limited time, customers who purchase a select 4G T-Mobile® smartphone will receive a second smartphone of equal or lesser value for free, after a mail-in rebate card, making it more affordable than ever for ... read more